CTOs on the Move

La Jolla Pharmaceutical Company

www.ljpc.com

 
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other ...
  • Number of Employees: 25-100
  • Annual Revenue: $100-250 Million
  • www.ljpc.com
  • 4370 La Jolla Village Dr Ste 400
    San Diego, CA USA 92122
  • Phone: 858.207.4264

Executives

Name Title Contact Details

Similar Companies

Elevation Pharmaceuticals

Elevation Pharmaceuticals is a biopharmaceutical company focused on developing new inhaled therapies for patients with respiratory disease.

Tweed

Tweed and our sister company Tweed Farms are wholly owned subsidiaries of Tweed Marijuana Inc., traded on the TSX Venture Exchange as TWD. We are a Canadian company licensed under the Marihuana for Medical Purposes Regulations. We strive to supply a wide selection of marijuana, as diverse as the patients who trust us with their patronage.

XTuit

XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.

International Oncology Network

International Oncology Network is a Frisco, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.